Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR)

Respiratory Medicine

Volumn 108, Issue 12, 2014, Pages 1723-1732

  Schleich, F ^a   Brusselle, G ^b   Louis, R ^a   Vandenplas, O ^c   Michils, A ^d   Pilette, C ^e   Peche, R ^f   Manise, M ^a   Joos, G ^b  

^a CHU SART TILMAN   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^d ERASME HOSPITAL   (Belgium)

^e CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^f Centre Hospitalier Universitaire de Charleroi   (Belgium)

Author keywords

Comorbidities; Inflammation; Phenotype; Severe asthma

Indexed keywords

IMMUNOGLOBULIN E ANTIBODY; METHYLPREDNISOLONE; BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; GLUCOCORTICOID;

ADULT; ARTICLE; ASPIRIN EXACERBATED RESPIRATORY DISEASE; ASTHMA; BELGIAN; BELGIUM; CHRONIC RHINOSINUSITIS; COHORT ANALYSIS; COMORBIDITY; CORTICOSTEROID THERAPY; CROSS-SECTIONAL STUDY; DEPRESSION; EOSINOPHIL COUNT; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GASTROESOPHAGEAL REFLUX; GENETIC HETEROGENEITY; HISTORY; HUMAN; MAJOR CLINICAL STUDY; MALE; NOSE POLYP; OBESITY; PHENOTYPE; PRIORITY JOURNAL; REGISTER; RHINITIS; SMOKING; AGED; BLOOD; CLINICAL TRIAL; EDUCATIONAL STATUS; EMPLOYMENT; EOSINOPHIL; HOSPITALIZATION; LEUKOCYTE COUNT; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; QUALITY OF LIFE; STATISTICS AND NUMERICAL DATA; VITAL CAPACITY;

ADRENERGIC BETA-1 RECEPTOR AGONISTS; ADULT; AGED; ASTHMA; BELGIUM; COMORBIDITY; CROSS-SECTIONAL STUDIES; EDUCATIONAL STATUS; EMPLOYMENT; EOSINOPHILS; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HOSPITALIZATION; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PHENOTYPE; QUALITY OF LIFE; REGISTRIES; VITAL CAPACITY;

EID: 84927691184     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2014.10.007     Document Type: Article

References (45)

1. Sorkness RL, Bleecker ER, Busse WW, Calhoun WJ, Castro M, Chung KF, et al. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Phys 2008 Feb; 104(2): 394-403.
2. Wu AC, Tantisira K, Li L, Schuemann B, Weiss S. Repeatability of response to asthma medications. J Allergy Clin Immunol 2009 Feb; 123(2): 385-90.
3. Accordini S, Corsico A, Cerveri I, Gislason D, Gulsvik A, Janson C, et al. The socio-economic burden of asthma is substantial in Europe. Allergy 2008 Jan; 63(1): 116-24.
4. Bel EH, Sousa A, Fleming L, Bush A, Chung KF, Versnel J, et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the innovative medicine initiative (IMI). Thorax 2011 Oct; 66(10): 910-7.
5. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014 Feb; 43(2): 343-73.
6. Wenzel SE Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012 May; 18(5): 716-25.
7. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European network for understanding mechanisms of severe asthma. Eur Respir J 2003 Sep; 22(3): 470-7.
8. Kupczyk M, Haque S, Sterk PJ, Nizankowska-Mogilnicka E, Papi A, Bel EH, et al. Detection of exacerbations in asthma based on electronic diary data: results from the 1-year prospective BIOAIR study. Thorax 2013 Jul; 68(7): 611-8.
9. Chipps BE, Zeiger RS, Borish L, Wenzel SE, Yegin A, Hayden ML, et al. Key findings and clinical implications from the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study. J Allergy Clin Immunol 2012 Aug; 130(2): 332-42.
10. Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, Ameredes BT, Bacharier L, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007 Feb; 119(2): 405-13.
11. Heaney LG, Brightling CE, Menzies-Gow A, Stevenson M, Niven RM. Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry. Thorax 2010 Sep; 65(9): 787-94.
12. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med 2000 Dec; 162(6): 2341-51.
13. Louis R, Sele J, Henket M, Cataldo D, Bettiol J, Seiden L, et al. Sputum eosinophil count in a large population of patients with mild to moderate steroid-naive asthma: distribution and relationship with methacholine bronchial hyperresponsiveness. Allergy 2002 Oct; 57(10): 907-12.
14. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992 Feb; 47(2): 76-83.
15. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999 Oct; 14(4): 902-7.
16. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004 Jan; 113(1): 59-65.
17. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011 Sep 1; 184(5): 602-15.
18. Delvaux M, Henket M, Lau L, Kange P, Bartsch P, Djukanovic R, et al. Nebulised salbutamol administered during sputum induction improves bronchoprotection in patients with asthma. Thorax 2004 Feb; 59(2): 111-5.
19. Popov TA, Pizzichini MM, Pizzichini E, Kolendowicz R, Punthakee Z, Dolovich J, et al. Some technical factors influencing the induction of sputum for cell analysis. Eur Respir J 1995 Apr; 8(4): 559-65.
20. Schleich FN, Manise M, Sele J, Henket M, Seidel L, Louis R. Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med 2013 Feb 26; 13(1): 11.
21. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012 Aug 18; 380(9842): 651-9.
22. Schleich FN, Seidel L, Sele J, Manise M, Quaedvlieg V, Michils A, et al. Exhaled nitric oxide thresholds associated with a sputum eosinophil count >/=3% in a cohort of unselected patients with asthma. Thorax 2010 Dec; 65(12): 1039-44.
23. McGrath KW, Icitovic N, Boushey HA, Lazarus SC, Sutherland ER, Chinchilli VM, et al. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med 2012 Mar 15; 185(6): 612-9.
24. Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011 Nov 15; 184(10): 1125-32.
25. Bousquet J, Rabe K, Humbert M, Chung KF, Berger W, Fox H, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007 Jul; 101(7): 1483-92.
26. Dolan CM, Fraher KE, Bleecker ER, Borish L, Chipps B, Hayden ML, et al. Design and baseline characteristics of the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2004 Jan; 92(1): 32-9.
27. Tantisira KG, Colvin R, Tonascia J, Strunk RC, Weiss ST, Fuhlbrigge AL. Airway responsiveness in mild to moderate childhood asthma: sex influences on the natural history. Am J Respir Crit Care Med 2008 Aug 15; 178(4): 325-31.
28. Schleich FN, Chevremont A, Paulus V, Henket M, Manise M, Seidel L, et al. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur Respir J 2014 Feb 13; 44: 14-6.
29. Thomson NC, Chaudhuri R, Heaney LG, Bucknall C, Niven RM, Brightling CE, et al. Clinical outcomes and inflammatory bio-markers in current smokers and exsmokers with severe asthma. J Allergy Clin Immunol 2013 Apr; 131(4): 1008-16.
30. Gaga M, Papageorgiou N, Yiourgioti G, Karydi P, Liapikou A, Bitsakou H, et al. Risk factors and characteristics associated with severe and difficult to treat asthma phenotype: an analysis of the ENFUMOSA group of patients based on the ECRHS questionnaire. Clin Exp Allergy 2005 Jul; 35(7): 954-9.
31. Brusselle G, Michils A, Louis R, Dupont L, Van de MB, Delobbe A, et al. "Real-life™ effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med 2009 Nov; 103(11): 1633-42.
32. Vandenplas O, Dramaix M, Joos G, Louis R, Michils A, Verleden G, et al. The impact of concomitant rhinitis on asthma-related quality of life and asthma control. Allergy 2010 Oct; 65(10): 1290-7.
33. Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008 Aug 1; 178(3): 218-24.
34. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010 Feb 15; 181(4): 315-23.
35. Pavord ID Asthma control, airway responsiveness and airway inflammation. Clin Exp Allergy 2009 Dec; 39(12): 1780-2.
36. Louis R, Lau LC, Bron AO, Roldaan AC, Radermecker M, Djukanovic R. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 2000 Jan; 161(1): 9-16.
37. Duncan CJ, Lawrie A, Blaylock MG, Douglas JG, Walsh GM. Reduced eosinophil apoptosis in induced sputum correlates with asthma severity. Eur Respir J 2003 Sep; 22(3): 484-90.
38. Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999 Nov; 160(5 Pt 1): 1532-9.
39. Miranda C, Busacker A, Balzar S, Trudeau J, Wenzel SE. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2004 Jan; 113(1): 101-8.
40. Leblanc A, Botelho C, Coimbra A, da Silva JP, de Castro ED, Cernadas JR. Assessment of asthma control: clinical, functional and inflammatory aspects. Eur Ann Allergy Clin Immunol 2013 May; 45(3): 90-6.
41. Ozoh OB, Okubadejo NU, Chukwu CC, Bandele EO, Irusen EM. The ACT and the ATAQ are useful surrogates for asthma control in resource-poor countries with inadequate spirometric facilities. J Asthma 2012 Dec; 49(10): 1086-91.
42. Carranza Rosenzweig JR, Edwards L, Lincourt W, Dorinsky P, ZuWallack RL. The relationship between health-related quality of life, lung function and daily symptoms in patients with persistent asthma. Respir Med 2004 Dec; 98(12): 1157-65.
43. Liu Y, Zhang S, Li DW, Jiang SJ. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials. PLoS One 2013; 8(3):e59872.
44. Lavoie KL, Bacon SL, Labrecque M, Cartier A, Ditto B. Higher BMI is associated with worse asthma control and quality of life but not asthma severity. Respir Med 2006 Apr; 100(4): 648-57.
45. Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 2013 Apr; 68(4): 322-9.